Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COMBAT-MS (COMparison Between All immunoTherapies for Multiple Sclerosis) A prospective long-term cohort study of safety, efficacy and patient's satisfaction of MS disease modulatory treatments in relapsing-remitting multiple sclerosis

Next Previous
Trial Profile

COMBAT-MS (COMparison Between All immunoTherapies for Multiple Sclerosis) A prospective long-term cohort study of safety, efficacy and patient's satisfaction of MS disease modulatory treatments in relapsing-remitting multiple sclerosis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Alemtuzumab; Dimethyl fumarate; Fingolimod; Glatiramer acetate; Interferon alpha-1b; Interferon beta-1a; Interferon beta-1b; Natalizumab; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms COMBAT-MS

    • Most Recent Events

    • 13 Oct 2023 Results describing the difference in incidence of psychiatric comorbidities and productivity loss across previously defined clusters of individual fatigue trajectories within the RRMS COMBAT-MS cohort, presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
    • 13 Oct 2023 Results comparing clinical and imaging outcomes, and sNfL Z-scores in People with MS starting a first disease ease modulatory therapy or doing a first DMT switch with follow up over 3 years, presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.
    • 25 Feb 2023 Results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top